With the exception of NTRK and RET fusions, all of the US FDA approvals are tumor-specific: ALK (non-small cell lung cancer [NSCLC]), ROS1 (NSCLC), and FGFR2-3 (urothelial, cholangiocarcinoma). This evidence concerns the gene ALK and non-small cell lung carcinoma.